Arvinas (ARVN) Stock Price, News & Analysis

Company Overview

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach, known as targeted protein degradation, uses proprietary PROTAC technology to direct specific proteins to the cell’s natural disposal machinery. Arvinas applies this platform primarily to cancer and other serious diseases in which abnormal or unwanted proteins contribute to disease progression.

Arvinas’ pipeline has included vepdegestrant, formerly known as ARV-471, an investigational oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer. The company has also developed bavdegalutamide, formerly known as ARV-110, an investigational androgen receptor degrader for prostate cancer. Arvinas continues to evaluate additional targeted protein degradation programs across oncology and other therapeutic areas.

Founded in 2013 by Yale University scientist Craig Crews, Arvinas is headquartered in New Haven, Connecticut. The company has entered into strategic collaborations with larger pharmaceutical companies, including Pfizer, to support the development and potential commercialization of selected programs. John Houston, Ph.D., has served as Arvinas’ president and chief executive officer.

Key Stats

• Today's Range: $8.39 to $8.70
• 50-Day Range: $8.01 to $9.68
• 52-Week Range: $6.97 to $14.51
• Volume: 1.47 million shs
• Average Volume: 576,112 shs
• Market Capitalization: $541.97 million
• P/E Ratio: 84.01
• Dividend Yield: N/A
• Price Target: $14.17
• Consensus Rating: Hold

Arvinas Stock Analysis - MarketRank™

Arvinas scored higher than 58% of companies evaluated by MarketBeat, and ranked 461st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Arvinas has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Arvinas has a consensus price target of $14.17, representing about 68.7% upside from its current price of $8.40.

Amount of Analyst Coverage

Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arvinas are expected to decrease in the coming year, from $0.05 to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arvinas is 84.01, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.71.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arvinas is 84.01, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.99.

Price to Book Value per Share Ratio

Arvinas has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.88% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 8.04.

Change versus previous month

Short interest in Arvinas has recently increased by 16.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arvinas does not currently pay a dividend.

Dividend Growth

Arvinas does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

Arvinas has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Arvinas this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Arvinas to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,479.00 in company stock.

Percentage Held by Insiders

7.30% of the stock of Arvinas is held by insiders.

Percentage Held by Institutions

95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/14/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARVN
• CIK: 1655759
• Web: www.arvinas.com
• Phone: (203) 535-1456
• Fax: N/A
• Employees: 246
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Arvinas: $14.17
• High Price Target: $21.00
• Low Price Target: $6.00
• Potential Upside/Downside: +68.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.10
• Trailing P/E Ratio: 84.01
• Forward P/E Ratio: 168.00
• P/E Growth: N/A
• Net Income: -$80.80 million
• Net Margins: 2.94%
• Pretax Margin: 3.16%
• Return on Equity: 1.91%
• Return on Assets: 1.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.91
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $262.60 million
• Price / Sales: 2.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.76 per share
• Price / Book: 1.24

Miscellaneous

• Outstanding Shares: 64,520,000
• Free Float: 59,811,000
• Market Cap: $541.97 million
• Optionable: Optionable
• Beta: 1.75